Form 4: Apellis Pharmaceuticals Chief People Officer Sells Shares to Cover Tax Obligations

Karen Lewis, Chief People Officer at Apellis Pharmaceuticals, sold 364 shares of common stock to cover tax withholding obligations related to restricted stock units.

Summary

• Karen Lewis, the Chief People Officer of Apellis Pharmaceuticals, sold 364 shares of the company's common stock on January 29, 2025.
• The sale was executed at a price of $29.5236 per share.
• This transaction was to cover tax withholding obligations related to restricted stock units that vested on January 28, 2025.
• Following the transaction, Ms. Lewis directly owns 70,251 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale by Karen Lewis is consistent with standard practices for managing executive compensation and tax liabilities.

Stakeholder Impact

• This transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Apellis Pharmaceuticals, Karen Lewis, stock sale, insider trading, Form 4, restricted stock units, tax withholding, executive compensation